EGFR status is an increasingly important analysis for patients diagnosed with lung cancer. The receptor status and mutation identified helps to ensure that each patient receives the appropriate treatment with tyrosine kinase inhibitors. This project collected data from all testing laboratories that provide this service in England and linked this information to the data collected by the National Cancer Registration Service. This combined comprehensive data source now provides the facility to assess the uptake and use of these molecular tests across the whole of England and allows correlation of this intervention with outcome and treatment pathways. It also allows identification of in-equitable provision and highlights potential benefits of appropriate early testing and triage.
Work sponsored by AstraZeneca.